Search Results: (10 results)

This study will determine if high intensity aerobic and resistance training (with supervised exercise) plus psychosocial support increases overall survival compared to psychosocial support alone (with self-directed exercise) in patients with metastatic castrate-resistant prostate cancer. NOTE: This study is no longer enrolling people. 

NOTE: This study is no longer enrolling. 

The goal of this research study is to test the effects of online genetic education alone or in combination with telephone genetic counseling in order to compare the two methods and the stress a person feels about their risk of cancer.  NOTE: This study has closed for enrollment.

Dr. C. Neill Epperson and her research team at the Penn Center for Women's Behavioral Wellness are studying the effects of a stimulant medication called Vyvanse® on memory and attention in women who had surgery to remove their ovaries to lower their risk for ovarian cancer (risk-reducing salpingo-oophorectomy or RRSO). NOTE: The study offers travel reimbursements and hotel accommodations for those eligible to participate. 

NOTE: This study is no longer enrolling people. 

The OlympiA trial is the first major study to test a targeted therapy for people with BRCA mutation-associated breast cancer in the adjuvant setting (after surgery) for people with earlier-stage (stage 2 or stage 3) cancers. The OlympiA trial has now completed enrollment. Interim results from OlympiA were presented at the 2021 ASCO Annual Symposium. 

In this study, researchers wanted to determine the optimal amount of exercise needed to change certain factors associated with breast cancer risk for post-menopausal, high-risk women. 

NOTE:  THIS STUDY ENROLLMENT HAS CLOSED

PROMPT is an online research registry for people who have had genetic panel testing (also known as multiplex testing) — a newer form of genetic testing that looks for mutations in several different genes at once. All genes on the panels have been linked to an increased risk of cancer, but some risks are better known than others.

The goal of the PROMPT Registry is to follow people with mutations or variants in genes on these panels, so that patients, physicians, and researchers can more clearly understand these lesser-known risks.

This is a study looking at folate deficiency (lack of folic acid in the blood) in patients who take the drug olaparib (Lynparza) to treat their advanced ovarian or breast cancer. The main goal of this study is to measure how often and when folate deficiency is most likely to occur; and to learn more about whether giving folic acid supplements (vitamins) will help delay or avoid deficiency in these patients. Folate deficiency can cause side effects and lead to reduction or stopping of treatment with olaparib.  NOTE: This study is no longer enrolling people.

The goal of the study is to evaluate the anti-cancer activity of Talazoparib (a type of treatment known as a PARP inhibitor) in patients with advanced breast cancer with specific genetic mutations based on a blood, saliva, or tumor test. See the clinicaltrials.gov listing for additional information. NOTE: This study is no longer enrolling people.

ARIEL4 is a treatment study for women with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA1 or BRCA2 mutation. ARIEL4 is designed to evaluate rucaparib against standard of care chemotherapy in women who have had at least two prior chemotherapy regimens.  UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS